Targeting disease activity to predict and prevent damage in obstructive airway diseases [0.03%]
针对疾病活动度预测和预防气道阻塞性疾病的损害
Ian D Pavord
Ian D Pavord
The discovery of clinically accessible biomarkers that identify patients with obstructive airway disease who are at risk of adverse outcomes along with the availability of highly effective targeted treatments has increased interest in earli...
Small Molecules: What makes them 'small' and why is that important? What can we expect? [0.03%]
小分子：是什么因素使其“小”？为什么这一点很重要？我们对其有哪些期待？
Raffi Tachdjian
Raffi Tachdjian
Just when newer technologies threaten to render them obsolete, small molecule drugs are under way to becoming first-in-class drugs in allergy and immunology. This is why understanding how they fit in to the treatment paradigm is key for mod...
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2 [0.03%]
瑞美替尼对疾病控制、睡眠和生活质量的影响：REMIX-1/2三期临床试验分析
Giselle Mosnaim,Sarbjit Saini,Mark Lebwohl et al.
Giselle Mosnaim et al.
Background: Chronic spontaneous urticaria (CSU) substantially reduces patient quality of life (QoL); therefore, it is crucial to include QoL-related patient-reported outcome measures (PROMs) when assessing treatment effic...
Longitudinal Prescribing Patterns of Mammalian Allergen Immunotherapy Across the U.S. Military Healthcare System from 2005-2024 [0.03%]
2005年至2024年美国军事医疗系统中哺乳动物过敏免疫疗法的纵向处方模式
Elizabeth A Pepper,Brandon J Schornack,Michael Zamani et al.
Elizabeth A Pepper et al.
Luz Fonacier,Stephanie Mawhirt,Heather Stern et al.
Luz Fonacier et al.
Practice Trends in Allergy and Immunology in the United States from 2015 to 2023 [0.03%]
2015至2023年美国变态反应和临床免疫学的实践趋势
Bryan Witt,Robin Cheung,Syed Jaffery et al.
Bryan Witt et al.
Reductions in Immunoglobulin Levels, Atopic Disease, and Asthma Following CAR T-Cell Therapy [0.03%]
CAR-T细胞治疗后的免疫球蛋白水平降低、特应性疾病和哮喘症状减少
Ahmed Elmoursi,Lingxiao Zhang,Marcela V Maus et al.
Ahmed Elmoursi et al.
Geospatial and Insurance Barriers to Allergist Access Across the Midwest [0.03%]
中西部地区过敏症医生就诊的地理空间和保险障碍
Claire King,Jiafeng Zhu,Andrea Arlene Pappalardo et al.
Claire King et al.
Background: Allergist access in the United States is limited by geographic and insurance-related barriers. The national Medicaid acceptance rate among allergists was previously reported at 55.5%, but access across the Mid...
Non-steroidal anti-inflammatory drugs in the treatment of uterine anaphylaxis [0.03%]
非甾体抗炎药在子宫过敏反应治疗中的应用
Janet Luu,Edsel Abud,Jennifer Namazy et al.
Janet Luu et al.
Unique and Shared Patterns of Chemosensory Dysfunction Distinguish Chronic COVID-19 and Aspirin-Exacerbated Respiratory Disease [0.03%]
独特的化学感觉功能障碍模式可区分慢性新冠肺炎和阿司匹林加重呼吸系统疾病
Dante G Minichetti,Tiffany Dharia,Amelia Boyd et al.
Dante G Minichetti et al.
Background: Persistent chemosensory dysfunction (CSD) occurs in both COVID-19 and aspirin-exacerbated respiratory disease (AERD). The similarities and differences in chemosensory experiences of these two conditions remain...